Company: NCEL
Filing Date: 2025-03-03
Form Type: F-4/A
Source: 0001213900-25-018981
Chunk: 805

Company: NewcelX Ltd.
Filing Date: 2025-03-03
Form: F-4/A
Chunk 805
---
 created based on Swiss law upon the exercise of the respective warrants by the investors. On March 5, 2022, the Company entered into the Sales Agreement with Virtu, as sales agent. On April 13, 2022, the Company reduced the amount that may be sold pursuant to the Sales Agreement to $230,000. The Company will pay Virtu a commission rate of up to 3.0% of the gross proceeds from each sale of common shares and has agreed to provide Virtu with customary indemnification and contribution rights. The Company will also reimburse Virtu for certain specified expenses in connection with entering into the Sales Agreement. Under the Sales Agreement, common shares will be offered and sold pursuant to the Company’s shelf registration statement on Form F -3(File No. 333 -262489), declared effective by the Securities and Exchange Commission on February 11, 2023. In addition, under the Sales Agreement, sales of common shares may be made by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended. The Company has no obligation to sell any of the common shares under the Sales Agreement and may at any time suspend the offering of its common shares upon notice and subject to other conditions. Warrants:

The following table summarizes the common share warrant activity for the year ended December 31, 2023:

| Balance at January 1, 2023   |     | 19,045,043 |   |
| Issuances                    |     |          0 |   |
| Exercises                    |     |         (0 | ) |
| Balance at December 31, 2023 |     | 19,045,043 |   |

Annex F-136 NLS PHARMACEUTICS LTD.
NOTES TO THE FINANCIAL STATEMENTS

The intrinsic value of exercisable but unexercised in -the-moneycommon share warrants at December 31, 2023 was $ 3,304,492. Treasury Shares: In the first half of 2023, the Company created treasury shares from its authorized capital in order to use them for its Standby Equity Distribution Agreement (the “SEDA”) that has been executed with YA II PN, Ltd., as discussed above. On December 31, 2023, the Company held 3,242,887treasury shares for financing arrangements (2022: no such treasury shares were